1173 results about "Placenta" patented technology

The present invention provides compositions and methods of using embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The embryonic-like stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Cells derived from postpartum tissue such as the umbilical cord and placenta, pharmaceutical compositions comprising such cells, and methods for using such cells and pharmaceutical compositions to treat patients having a neurodegenerative condition of the substantia nigra or striatum, such as Parkinson's disease, are provided.

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

The present invention concerns methods and compositions for inhibiting angiogenesis and / or tumor growth, survival and / or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and / or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.

The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and / or minerals, DHA, one or more DHA taste-masking agents and, optionally, one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant. The food bars of the invention generally comprise one or more vitamins and minerals recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant in an amount that is effective for enhancing the nutrition of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, and that is not harmful to developing fetuses or breast-feeding babies, including calcium in an amount above 1,000 mg, DHA in an amount that is effective for providing, or increasing the supply of, DHA to a developing fetus or baby through a placenta or breast milk, one or more DHA taste-masking agents in an amount that is effective for masking the taste of DHA, and that is not harmful to developing fetuses or breast-feeding babies and, optionally, one or more anti-constipation and regularity-maintaining agents in an amount that is effective for reducing or eliminating constipation, and that is not harmful to developing fetuses or breast-feeding babies, from about 0 to about 99 weight percent of carbohydrates, from about 0 to about 80 weight percent of proteins, and from about 0 to about 60 weight percent of fats.